Velo3D, Inc. Form 8-K Summary
Reporting period and context: Filed December 28, 2023, with the earliest reported event on December 26, 2023. The filing reports a proposed equity and warrant financing, amendments to senior secured notes due 2026, and an NYSE minimum-share-price deficiency.
Financing and Financial Position
- Velo3D entered into securities purchase agreements for 36.0 million common shares and warrants to purchase 36.0 million additional shares.
- The purchase price is $0.50 per share and accompanying warrant, for expected gross proceeds of approximately $18.0 million, subject to closing conditions.
- The warrants are immediately exercisable at $0.565 per share and expire five years after issuance.
- The closing was expected on December 29, 2023. Proceeds are intended primarily for working capital, capital expenditures, and general corporate purposes.
- The placement agent will receive a 7.0% cash fee, expense reimbursement of up to $150,000, and warrants to purchase 1.8 million shares at $0.6215 per share.
- The Company expects to pay $25.0 million in cash to retire approximately $20.8 million of principal under its senior secured notes, plus accrued and unpaid interest. The filing indicates that this payment is expected to be funded from existing cash and made concurrently with the offering closing.
- The filing does not provide revenue, profit, cash-flow, margin, or liquidity balances for a comparable reporting period.
Material Changes Versus the Prior Position
- The note amendment eliminates a January 1, 2024 requirement to redeem $8.75 million of principal for $10.5 million plus accrued interest.
- It eliminates the requirement to maintain at least $35.0 million of unrestricted cash and cash equivalents.
- It defers from December 31, 2023 to January 31, 2024 the requirement to establish or expand an at-the-market offering program with at least $75.0 million of available capacity.
- The proposed financing would increase outstanding common shares by 36.0 million shares and could result in additional dilution if the warrants are exercised. The filing does not state the pre-offering share count.
NYSE Listing, Outlook, and Risks
- On December 26, 2023, Velo3D received informal notice that the NYSE would issue a written deficiency notice because its average closing share price was below $1.00 over 30 consecutive trading days.
- The Company intends to notify the NYSE that it will cure the deficiency. It has six months after receiving the formal notice to regain compliance.
- Compliance requires a closing price of at least $1.00 and a 30-trading-day average closing price of at least $1.00 on the applicable measurement date.
- The common stock is expected to remain listed during the cure period, subject to other NYSE requirements. Failure to regain compliance could result in delisting.
- Management’s stated use of proceeds is working capital, capital expenditures, and general corporate purposes; the filing provides no operating forecast or revenue guidance.
- Key execution risks include completion of the offering, availability of cash for the note repayment, compliance with financing conditions, future capital needs, warrant-related dilution, and the ability to cure the NYSE deficiency.
Investor Verification Priorities
- Confirm whether the December 29, 2023 offering and $25.0 million note repayment closed as planned and determine actual net proceeds after fees and expenses.
- Verify the Company’s post-transaction cash balance, remaining debt principal, interest obligations, and compliance with amended note covenants.
- Review the post-offering share count and the potential dilution from the investor and placement-agent warrants.
- Track the formal NYSE deficiency notice, the six-month cure deadline, and subsequent share-price compliance.
- Assess whether additional financing or an expanded at-the-market program may be required after the deferred January 31, 2024 obligation.